Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Pharma Mergers: FTC Should Consider Monitoring R&D, Assessing PBM Contracts, Experts Advise

Jun 15 2022

• By Brenda Sandburg

M&A — Pharmaceutical mergers may face new hurdles in getting US FTC clearance • Source: Shutterstock

Related Content

Pharma Mergers May Have Tougher Time Clearing FTC Under New Review Scheme

Mar 17 2021

Amgen’s Rebate Bundling Makes It ‘Economically Unfeasible’ For Regeneron To Sell Praluent

Jun 01 2022

FTC Launches ‘Colonoscopy’ Into PBM Practices, Including Focus On Consumer Costs, Access

Jun 09 2022

Related Companies

AbbVie Inc.

Allergan plc

Pfizer Inc.

Regeneron Pharmaceuticals, Inc.

Additional Topics

United States Enforcement Legal Issues M & A Commercial Policy BioPharmaceutical

More from Compliance

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window